



09-16-03

PATENT #17

RECEIVED  
SEP 22 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Houtzager et al.

Serial No.: 09/882,621

Filed: June 15, 2001

For: CHIMAERIC PHAGES

Confirmation No.: 8472

Examiner: M. Hill

Group Art Unit: 1648

Attorney Docket No.: 2578-4957US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV325784625US

Date of Deposit with USPS: September 15, 2003

Person making Deposit: Chris Haughton

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56 (b) exists.

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
EP 1 266 963 A1	12-18-2002	Crucell Holland B.V.
WO 02/103012 A1	12-27-2002	Crucell Holland B.V.

Other Documents

BALINT et al., Antibody engineering by parsimonious mutagenesis, Gene, 1993, pp. 109-18, Vol. 137.

BARBAS III et al., In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity, Proc. Natl. Acad. Sci., April 1994, pp. 3809-13, Vol. 91, USA.

BASS et al., Hormone Phage: An Enrichment Method for Variant Proteins With Altered Binding Properties, Proteins: Structure, Function, and Genetics, 1990, pp. 309-14, Vol. 8.

BEEKWILDER et al., A phagemid vector using the E. coli phage shock promoter facilitates phage display of toxic proteins, Gene, 1999, pp. 23-31, Vol. 228.

BEREK et al., Mutation Drift and Repertoire Shift in the Maturation of the Immune Response, Immunological Reviews, 1987, pp. 23-41, No. 96.

BURTON et al., Human Antibodies from Combinatorial Libraries, Advances in Immunology, pp. 191-280, Vol. 57.

CHATELLIER et al., Interdomain interactions within the gene 3 protein of filamentous phage, FEBS Letters, 1999, pp. 371-74, Vol. 463.

CRISSMAN et al., Gene-III Protein of Filamentous Phages: Evidence for a Carboxyl-Terminal Domain with a Role in Morphogenesis, Virology, 1984, pp. 445-55, Vol. 132.

CWIRLA et al., Peptides on phage: A vast library of peptides for identifying ligands, Proc. Natl. Acad. Sci., August 1990, pp. 6378-82, Vol. 87.

DE KRUIF et al., Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-synthetic Phage Antibody Display Library with Designed CDR3 Regions, J. Mol. Biol., 1995, pp. 97-105, Vol. 248.

DE KRUIF et al., Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library, *Proc. Natl. Acad. Sci.*, April 1995, pp. 3938-42, Vol. 92, USA.

DENG et al., Interaction of the Globular Domains of pIII Protein of Filamentous Bacteriophage fd with the F-Pilus of *Escherichia coli*, *Virology*, 1999, pp. 271-77, Vol. 253.

DEVLIN et al., Random Peptide Libraries: A Source of Specific Protein Binding Molecules, *Science*, July 27, 1990, pp. 404-06, Vol. 249.

DUENAS et al., Clonal Selection and Amplification of Phage Displayed Antibodies by Linking Antigen Recognition and Phage Replication, *Bio/Technology*, October 1994, pp. 999-1002, Vol. 12.

DUENAS et al., Novel helper phage design: intergenic region affects the assembly of bacteriophages and the size of antibody libraries, *FEMS Microbiology Letters*, 1995, pp. 317-22, Vol. 125.

FELICI et al., Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognized by a protective monoclonal antibody against the *Bordetella pertussis* toxin from phage peptide libraries, *Gene*, 1993, pp. 21-27, Vol. 128.

HAWKINS et al., Selection of Phage Antibodies by Binding Affinity, Mimicking Affinity Maturation, *J. Mol. Biol.*, 1992, pp. 889-96, Vol. 226.

HOLLIGER et al., A conserved infection pathway for filamentous bacteriophages is suggested by the structure of the membrane penetration domain of the minor coat protein g3p from phage fd, *Structure*, 1997, pp. 265-75, Vol. 5, No. 2.

HOOGENBOOM et al., Designing and optimizing library selection strategies for generating high-affinity antibodies, *TIB Tech*, February 1997, pp. 62-70, Vol. 15.

KREBBER et al., Co-selection of cognate antibody--antigen pairs by selectively-infective phages, *FEBS Letters*, 1995, pp. 227-31, Vol. 377.

KREBBER et al., Selectively-infective Phage (SIP): A Mechanistic Dissection of a Novel in vivo Selection for Protein-ligand Interactions, *J. Mol. Biol.* 1997, pp. 607-18, Vol. 268.

KRISTENSEN et al., Proteolytic selection for protein folding using filamentous bacteriophages, *Folding & Design*, pp. 321-28, Vol. 3, No. 5.

LOW et al., Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain, *J. Mol. Biol.*, 1996, pp. 359-68, Vol. 260.

LUBKOWSKI et al., The structural basis of phage display elucidated by the crystal structure of the N-terminal domains of g3p, *Nature Structural Biology*, February 1998, pp. 140-47, Vol. 5, No. 2.

LUBKOWSKI et al., Filamentous phage infection: crystal structure of g3p in complex with its coreceptor, the C-terminal domain of TolA, *Structure*, 1999, pp. 711-22, Vol. 7, No. 6.

LUZZAGO et al., Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained peptides, *Gene*, 1993, pp. 51-57, Vol. 128.

LOPEZ et al., Morphogenesis of Filamentous Bacteriophage f1: Orientation of Extrusion and Production of Polyphage, *Virology*, 1983, pp. 177-93, Vol. 127.

MODEL et al., The *Escherichia coli* phage-shock-protein (psp) operon, *Molecular Microbiology*, 1997, pp. 255-61, Vol. 24, No. 2.

NELSON et al., Filamentous Phage DNA Cloning Vectors: A Noninfective Mutant with a Nonpolar Deletion in Gene III, *Virology*, 1981, pp. 338-50, Vol. 108.

NILSSON et al., The Phage Infection Process: a Functional Role for the Distal Linker Region of Bacteriophage Protein 3, *Journal of Virology*, May 2000, pp. 4229-35, Vol. 74.

PRATT et al., Conditional Lethal Mutants of the Small Filamentous Coliphage M13. II. Two Genes for Coat Proteins, *Virology*, 1969, pp. 42-53, Vol. 39.

RAKONJAC et al., Filamentous phage infection-mediated gene expression: construction and propagation of the gIII deletion mutant helper phage R408d3, *Gene*, 1997, pp. 99-103, Vol. 198.

RAKONJAC et al., Roles of pIII in Filamentous Phage Assembly, *J. Mol. Biol.* 1998, pp. 25-41, Vol. 282.

RIECHMANN et al., The C-Terminal Domain of TolA Is the Coreceptor of Filamentous Phage Infection of *E. coli*, *Cell*, July 25, 1997, pp. 351-60, Vol. 90.

RONDOT et al., A helper phage to improve single-chain antibody presentation in phage display, Nature Biotech, pp. 75-78, Vol. 19.

RUSSEL et al., Genetic Analysis of the Filamentous Bacteriophage Packaging Signal and of the Proteins That Interact with It, Journal of Virology, Aug. 1989, pp. 3284-95, Vol. 63, No. 8.

SMITH, Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion Surface, Science, June 14, 1985, pp. 1315-17, Vol. 228.

SPADA et al., Selectively Infective Phages (SIP), Biol. Chem., June 1997, pp. 445-56, Vol. 378.

VAUGHAN et al., Human antibodies by design, Nature Biotechnology, June 1998, pp. 535-39, Vol. 16.

WINTER et al., Man-made antibodies, Nature, January 24, 1991, pp. 293-99, Vol. 349.

YANG et al., CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range, J. Mol. Biol., 1995, pp. 392-403.

PCT International Search Report, PCT/NL02/00391, dated November 25, 2002, 3 pages.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming common inventors:

Attorney Docket No.: 2578-5016US  
Serial No.: 09/909,244  
Filing Date: 7/19/2001  
Title: A SELECTIVELY-EXPRESSED EPITOPE ON THE HUMAN  
CD38 MOLECULE DETECTED BY A PHAGE DISPLAY  
LIBRARY-DERIVED HUMAN SCFV ANTIBODY FRAGMENT

Attorney Docket No.: 2578-4514.1US  
Serial No.: 09/940,386  
Filing Date: 8/27/2001  
Title: DIFFERENTIALLY EXPRESSED EPITOPES AND USES  
THEREOF

Attorney Docket No.: 2183-5208US  
Serial No.: 10/016,516

Filing Date: 12/10/2001  
Title: A STRUCTURE FOR PRESENTING DESIRED PEPTIDE SEQUENCES

Attorney Docket No.: 2578-5420US  
Serial No.: 10/184,508  
Filing Date: 6/27/2002  
Title: USE OF A NATIVE EPITOPE FOR SELECTING EVOLVED BINDING MEMBERS FROM A LIBRARY OF MUTANTS OF A PROTEIN CAPABLE OF BINDING TO SAID EPITOPE

Attorney Docket No.: 2578-5420.1US  
Serial No.: 10/186,186  
Filing Date: 6/28/2002  
Title: USE OF A NATIVE EPITOPE FOR SELECTING EVOLVED BINDING MEMBERS FROM A LIBRARY OF MUTANTS OF A PROTEIN CAPABLE OF BINDING TO SAID EPITOPE

Attorney Docket No.: 2183-5610US  
Serial No.: 10/316,194  
Filing Date: 12/10/2002  
Title: A STRUCTURE FOR PRESENTING DESIRED PEPTIDE SEQUENCES

Attorney Docket No.: 2578-5808US  
Serial No.: 10/382,361  
Filing Date: 3/5/2003  
Title: HEAVY CHAIN LIBRARIES

Attorney Docket No.: 2578-4728.1US  
Serial No.: 10/466,466  
Filing Date: 7/15/2003  
Title: NOVEL FIBRONECTIN EPITOPES AND PROTEINACEOUS MOLECULES CAPABLE OF BINDING SAID EPITOPES

Attorney Docket No.: 2183-5611US  
Serial No.: 60/432,906  
Filing Date: 12/10/2002  
Title: AFFINITY PROTEINS FOR CONTROLLED APPLICATION OF COSMETIC SUBSTANCES

Serial No.: 09/882,621

This Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits.

The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,



Krista Weber Powell  
Registration No. 47,867  
Attorney for Applicant(s)  
TRASKBRITT, P.C.  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: September 15, 2003  
KWP/bv

Enclosures: Form PTO-1449 or PTO/SB/08  
Copy of documents cited  
Check in the amount of \$180.00

Document in ProLaw